Biogen Inc (BIIB.OQ)
229.89USD
9:00pm BST
$5.49 (+2.45%)
$224.40
$224.03
$232.11
$223.10
820,501
720,046
$388.67
$216.13
About
Overall
| Beta: | 0.72 |
| Market Cap(Mil.): | $69,239.67 |
| Shares Outstanding(Mil.): | 211.43 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.50 | 29.30 | 32.55 |
| EPS (TTM): | 15.23 | -- | -- |
| ROI: | 17.59 | 14.23 | 13.83 |
| ROE: | 28.64 | 15.46 | 15.25 |
AbbVie says Humira rivals from Biogen, Amgen most aggressive so far
AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.
AbbVie says Humira rivals from Biogen, Amgen most aggressive so far
April 25 AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.
Biogen dips as strategy post Alzheimer's setback fails to impress
Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.
Biogen dips as strategy post Alzheimer's setback fails to impress
Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent.
UPDATE 3-Biogen dips as strategy post Alzheimer's setback fails to impress
* Co beats 1st-qtr profit and revenue estimates (Adds details from conference call, analyst comment)
Biogen first-quarter profit rises 20 percent
April 24 Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.
Biogen SMA drug price, Novartis estimates for its treatment far too high - U.S. group
ZURICH Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.
Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group
ZURICH, April 3 Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments said on Wednesday.
Biogen announces $5 billion buyback days after shelving Alzheimer's trials
Biogen Inc said on Monday it would buy back shares worth $5 billion (3.8 billion pounds), days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.
Biogen announces $5 billion buyback days after shelving Alzheimer's trials
Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.
Estimates